Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aminolevulinic acid - Medac

Next Previous
X
Search
Drug Profile

Aminolevulinic acid - Medac

Alternative Names: 5-ALA - Medac; 5-ALA - Photonamic; 5-ALA Patch; ALA - Medac; ALA-HCl; Alacare; Aminolevulinic acid HCl; Aminolevulinic acid hydrochloride - Medac; Effala; Gleolan; Gliolan; PD L 506; PD P 506 A; PD P 506 A-PDT

Latest Information Update: 18 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Photonamic
  • Developer LINK Healthcare; Medac; Medexus Pharmaceuticals; NX Development Corp; Photonamic; Specialised Therapeutics Australia; Spirig Pharma
  • Class Amino acids; Antianaemics; Antineoplastics; Diagnostic agents; Imaging agents; Keto acids; Levulinic acids; Nootropics; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Actinic keratosis; Glioma
  • Phase III Meningioma; Ovarian cancer
  • Phase II Glioblastoma; Onychomycosis

Most Recent Events

  • 30 May 2024 Phase-III clinical trials in Ovarian cancer (Newly diagnosed, First-line therapy, Recurrent) in USA (PO) (NCT05804370)
  • 07 Apr 2023 NX Development Corp plans a phase III trial for Ovarian cancer (Recurrent, Newly diagnosed, First-line therapy) in July 2023 (PO)(NCT05804370)
  • 19 Sep 2022 Launched for Glioma (Diagnosis) in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top